5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Circadian lifestyle determinants of immune checkpoint inhibitor efficacy

      review-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immune Checkpoint Inhibitors (ICI) have revolutionised cancer care in recent years. Despite a global improvement in the efficacy and tolerability of systemic anticancer treatments, a sizeable proportion of patients still do not benefit maximally from ICI. Extensive research has been undertaken to reveal the immune- and cancer-related mechanisms underlying resistance and response to ICI, yet more limited investigations have explored potentially modifiable lifestyle host factors and their impact on ICI efficacy and tolerability. Moreover, multiple trials have reported a marked and coherent effect of time-of-day ICI administration and patients’ outcomes. The biological circadian clock indeed temporally controls multiple aspects of the immune system, both directly and through mediation of timing of lifestyle actions, including food intake, physical exercise, exposure to bright light and sleep. These factors potentially modulate the immune response also through the microbiome, emerging as an important mediator of a patient’s immune system. Thus, this review will look at critically amalgamating the existing clinical and experimental evidence to postulate how modifiable lifestyle factors could be used to improve the outcomes of cancer patients on immunotherapy through appropriate and individualised entrainment of the circadian timing system and temporal orchestration of the immune system functions.

          Related collections

          Most cited references140

          • Record: found
          • Abstract: not found
          • Article: not found

          Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

            The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry. Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterisation of the immune tumour microenvironment.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

                Bookmark

                Author and article information

                Contributors
                URI : https://loop.frontiersin.org/people/2581900Role: Role: Role: Role: Role: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/2548041Role: Role: Role: Role: Role: Role:
                Role: Role: Role: Role: Role: Role:
                Role: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role:
                Role: Role: Role: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/1692989Role: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role:
                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                04 December 2023
                2023
                : 13
                : 1284089
                Affiliations
                [1] 1 Oncology Department, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board , Bangor, United Kingdom
                [2] 2 School of Medical Sciences, Bangor University , Bangor, United Kingdom
                [3] 3 Department of Acute Medicine, Ysbyty Gwynedd , Bangor, United Kingdom
                [4] 4 Cancer Chronotherapy Team, Warwick Medical School, University of Warwick , Coventry, United Kingdom
                [5] 5 Research Unit ‘Chronotherapy, Cancers and Transplantation’, Faculty of Medicine, Paris-Saclay University , Villejuif, France
                Author notes

                Edited by: Laura Senovilla, Spanish National Research Council (CSIC), Spain

                Reviewed by: Marina Maria Bellet, University of Perugia, Italy

                *Correspondence: Pasquale F. Innominato, pasquale.innominato@ 123456wales.nhs.uk
                Article
                10.3389/fonc.2023.1284089
                10727689
                38111535
                a62c829f-bed2-42b3-b230-9a3059303aed
                Copyright © 2023 Hughes, Shanaz, Ismail-Sutton, Wreglesworth, Subbe and Innominato

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 05 September 2023
                : 07 November 2023
                Page count
                Figures: 1, Tables: 1, Equations: 0, References: 140, Pages: 9, Words: 3989
                Funding
                Funded by: Cancer Research Wales , doi 10.13039/100009828;
                Award ID: DOESC-01
                The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Cancer Research Wales provided support for digital oncology projects. They were not involved in this manuscript’s conception, writing, review, or decision to submit.
                Categories
                Oncology
                Mini Review
                Custom metadata
                Cancer Immunity and Immunotherapy

                Oncology & Radiotherapy
                cancer,immunotherapy,circadian,diet,exercise,light,lifestyle
                Oncology & Radiotherapy
                cancer, immunotherapy, circadian, diet, exercise, light, lifestyle

                Comments

                Comment on this article